LY4256984
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 18, 2026
J6I-MC-OWAA: Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
(clinicaltrialsregister.eu)
- P1 | N=30 | Recruiting | Sponsor: Eli Lilly & Co.
New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
November 19, 2025
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders
November 13, 2025
Design of the multiple ascending dose (MAD) trial of UNC13A splice modulating ASO LY4256984 in patients with sporadic amyotrophic lateral sclerosis (ALS)
(ALS-MND 2025)
- "Results to date: The trial initiated enrollment in 2025 and plans to be conducted in ≥10 sites. We will test the safety and tolerability of intrathecally administered UNC13A splice modulating ASO LY4256984 in patients with sporadic ALS."
Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • TARDBP
August 05, 2025
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company
New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
1 to 4
Of
4
Go to page
1